Content area

|
|

Kolesterolsænkende behandling med PCSK9-inhibitorer

Forfatter(e)
Michael E. Røder1, Per Hildebrandt2, Heidi Storgaard3 & Merete Heitmann4 1) Steno Diabetes Center Odense, Odense Universitetshospital2) Frederiksberg Hjerteklinik3) Steno Diabetes Center Copenhagen4) Kardiologisk Afdeling, Bispebjerg Hospital

Ugeskr Læger 2018;180:V11170831
Reference: 
Ugeskr Læger 2018;180:V11170831
Blad nummer: 
Sidetal: 

Michael E. Røder, Per Hildebrandt, Heidi Storgaard &
Merete Heitmann:

Cholesterol-lowering treatment with PCSK9-inhibitors

Ugeskr Læger 2018;180:V11170831

Monoclonal antibodies inhibiting proprotein convertase subtilisin-kexin type 9 constitute a new class of lipid-lowering drugs. Currently, evolocumab and alirocumab are marketed. A recent cardiovascular outcome study with evolocumab has shown a cardiovascular (CV) event reduction of 15% in high-risk individuals at very low levels of low-density lipoproteins. The adverse event profile up to two years is mild. Treatment is very costly, and data on CV endpoints are still limited. Treatment is restricted to patients at very high risk of getting CV diseases and on a maximal tolerated statin and ezetimibe treatment in addition to dietary intervention.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Anne Gersdorff Korsgaard | 20/10
1 Kommentar
af Karen Brink Linnet | 19/10
1 Kommentar
af Thor Andersen Knudsen | 19/10
2 kommentarer
af Ole Lindgård Dollerup | 18/10
1 Kommentar
af Kristine Rasmussen | 18/10
1 Kommentar
af Camilla Bang | 16/10
1 Kommentar
af Tobias Ramm Eberlein | 15/10
6 kommentarer
af Frank Bang Nissen | 15/10
1 Kommentar